SCHEMBL4053992

SCHEMBL4053992

Nc1nc(-c2ccco2)c(-c2ccncc2)cc1NC(=O)C1CC1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.70
ADORA2B P29275 16/20 0.70
ADORA1 P30542 16/20 0.70
ADORA3 P0DMS8 11/20 0.70
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
GSK3B P49841 2/20 0.51
MAPK14 Q16539 2/20 0.51
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052164 0.80 ADORA2B (0.74) ADORA2AADORA2BADORA1ADORA3CYP3A4
SCHEMBL4049442 0.76 PIK3R1 (0.54) ADORA2AADORA2BADORA1ADORA3MAPK14
SCHEMBL3076172 0.75 ADORA2B (1.00) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL3069547 0.72 ADORA2B (1.00) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL3066805 0.72 ADORA2B (1.00) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL3064050 0.71 ADORA2A (0.64) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL1255284 0.71 L3MBTL1 (0.66) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL4052079 0.71 PIK3R1 (0.47) ADORA2AADORA2BADORA1ADORA3NPC1
SCHEMBL1256050 0.71 ALDH1A1 (0.74) ADORA2AADORA2BADORA1ADORA3CYP1A2
SCHEMBL3840501 0.71 PIK3R1 (0.49) ADORA2AADORA2BADORA1ADORA3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.